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Abstract
The Kitasato Symposium 2009: New Prospects for Cytokine
Inhibition was held in Berlin, Germany from 7 to 9 May 2009. The
key aims of this meeting were to bring together a group of front-line
researchers and rheumatologists to evaluate the use of cytokine
blockade and to examine the role of certain cytokines in the
pathogenesis of rheumatoid arthritis and other autoimmune
diseases. A keynote lecture delivered by Professor Jean-Michel
Dayer provided an up-to-date overview of the interactions occur-
ring between the immune system and acute phase proteins. Other
speakers discussed the role of cytokines in rheumatoid arthritis,
including their role in joint destruction, as well as their regulatory
role upon T cells and B cells. The involvement of cytokines in other
autoimmune diseases was also addressed.
Introduction
During May 2009 the first Kitasato meeting was held at the
Palais am Festungsgraben, Berlin in memory of Professor
Shibasaburo Kitasato (1853–1931), who worked in Berlin
between 1885 and 1892 together with Robert Koch, Emil
von Behring and other scientists. This 2-day meeting gathered
together a group of front-line researchers and rheumatologists
to discuss the protective and pathogenic role of cytokines in
rheumatoid arthritis (RA) and other autoimmune diseases.
Cytokine-related therapeutic approaches for these conditions
and their underlying mechanisms were also considered.
A key aim of this meeting was to bring together not only those
individuals with an interest in the clinical aspects of rheuma-
tology and biological therapies, but also those involved in
basic immunological research. Approximately 50 individuals
from around the world attended this meeting, which it is
hoped may be the first of many, thus furthering the develop-
ment of biological therapies and improving outcomes for
individuals with RA or other autoimmune diseases.
Keynote lecture
The meeting began with a keynote lecture delivered by
Professor Jean-Michel Dayer (Geneva, Switzerland). Professor
Dayer proposed that acute phase proteins, which were first
identified in patients with pneumococcal infections during the
1930s [1] and 1940s [2,3], may be the first cytokines to have
been identified.
Acute phase proteins can be positive (that is, their concen-
trations increase in response to inflammation – for example,
C-reactive protein, serum amyloid A) or negative (that is, their
concentrations decrease in response to inflammation – for
example, apolipoproteins that protect from inflammation by
inhibiting the contact between activated lymphocytes and
monocytes for the production of IL-1 and TNF) (Figure 1) [4].
Describing autoimmune diseases as a hyperactivity of the
immune system, and using IL-1 receptor agonist (IL-1Ra) and
apolipoprotein A1 as examples, Professor Dayer went on to
consider how cytokines interact with one another in the body
and the role that they might play in the development of
autoimmune diseases. Discussing the delicate balance that
exists between IL-1 and IL-1Ra, Professor Dayer noted that,
during inflammation, leptin produced by adipocytes can
stimulate the production of IL-1 by the hypothalamus
(Figure 2) [5]. Acting at this level, IL-1 becomes a cachexin
resulting in the loss of both adipose tissue and lean body
mass. The adipocytes also produce IL-1Ra, however, which is
able to block the cachectic action of IL-1 and increase
appetite [6].
Meeting report
Kitasato Symposium 2009: New Prospects for Cytokine Inhibition
Gerd R Burmester, Peter E Lipsky and Thomas Dörner, for the Kitasato Meeting Faculty*
CC12, Charite Universitätsmedizin Berlin, Chariteplatz 01, 10098 Berlin, Germany
Corresponding author: Thomas Dörner, thomas.doerner@charite.de
Published: 23 December 2009 Arthritis Research & Therapy 2009, 11:301 (doi:10.1186/ar2857)
This article is online at http://arthritis-research.com/content/11/6/301
© 2009 BioMed Central Ltd
*Kitasato Meeting Faculty: JR Kalden (Erlangen), JM Dayer (Geneva), R Kroczek (Berlin), W van den Berg (Nijmegen), S Rose-John (Kiel), S Nedospasov
(Berlin, Moscow), C Gabay (Geneva), M Vervoordeldonk (AMC/University of Amsterdam, Amsterdam), Ch Plater-Zyberk (Munich), M Löhning (Berlin), 
J Isaacs (Newcastle, UK), P Miossec (Lyon), T Kamradt (Jena), S Fillatreau (Berlin), E Neumann (Giessen/Bad Nauheim), L Padyukov (Stockholm), 
P Crow (New York City), L Rönnblom (Uppsala), J Sieper (Berlin).
APRIL = a proliferation-inducing ligand; ATAC = activation-induced, T-cell-derived and chemokine-related cytokine; BAFF = B-cell activating factor;
GM-CSF = granulocyte–macrophage colony-stimulating factor; IFN = interferon; IL = interleukin; IL-1Ra = IL-1 receptor antagonist; NF = nuclear
factor; RA = rheumatoid arthritis; Th = T helper; TNF = tumour necrosis factor.Arthritis Research & Therapy    Vol 11 No 6 Burmester et al.
Page 2 of 8
(page number not for citation purposes)
If used therapeutically, cytokines may offer a less toxic treat-
ment option for individuals with autoimmune disease owing to
their abilities to modulate inflammation. Moreover, recombi-
nant cytokines may offer novel treatment approaches for
individuals found to demonstrate mutations in genes respon-
sible for the production of cytokines.
Cytokines and arthritis
The involvement and therapeutic potential of lymphotactin
(activation-induced, T-cell-derived and chemokine-related
cytokine (ATAC)) in Th-cell autoimmune reactions was the
subject of a presentation by Professor Richard Kroczek
(Berlin, Germany).
ATAC was first cloned in both mice [7] and humans [8] more
than 15 years ago, and was initially believed to act as a
chemoattractant for lymphocytes [7]. Subsequent studies in
humans indicated that ATAC/lymphotactin was primarily
produced in the synovium of RA patients and so, given its
role as a chemoattractant, might be a key modulator for T-cell
trafficking in the pathogenesis of RA [9]. Studies using
murine models suggest that the receptor for ATAC/
lymphotactin is only present on CD8+ dendritic cells, such as
those found in the spleen, which, given the role of CD8 cells
in the development of self-tolerance by the immune system,
may be implicated in the development of autoimmunity.
Cartilage destruction and bone erosion are major problems in
RA, and studies have shown that these processes may be
mediated by cytokines. Murine arthritis models have
demonstrated the therapeutic potential of anti-TNFα and anti-
IL-1 antibodies [10]. During this session on cytokines and
arthritis, Professor Wim van den Berg (Nijmegen, The
Netherlands) postulated that different cytokines may
dominate at different stages of the inflammatory process. For
example, in early-stage collagen-induced arthritis both anti-
TNFα and anti-IL-1 treatments have been shown to be
effective [11]. Moreover, IL-17 – a T-cell cytokine expressed
in the synovium and synovial fluid of patients with RA – has
been shown to be a potent inducer of TNFα and IL-1, and is
involved in both the initiation and progression of murine
arthritis models [12]. IL-17 not only synergizes with TNFα, but
also enhances inflammation and destruction independent of
IL-1 and TNFα, making it an additional potential target for the
treatment of RA. As such, tailor-made treatment is required
for the different patient groups.
Professor Stefan Rose-John (Kiel, Germany) discussed the
inflammatory properties of IL-6 and the complexity of IL-6
signalling, together with the consequences of and various
techniques employed in IL-6 blockade. During his presenta-
tion, Professor Rose-John noted that all IL-6 signalling is
mediated via binding of the IL-6 receptor to the ubiquitously
expressed glycoprotein 130. The IL-6 receptor is normally
membrane bound and expressed only on hepatocytes and
some leukocytes; however, this receptor can be cleaved, or
shed, from the cell via the actions of a metalloprotease
(ADAM17), producing a soluble IL-6 receptor that can then
bind to cells which do not normally express this receptor. This
phenomenon, so-called trans-signalling, enables IL-6 to exert
its effects upon a much wider range of cell types, including
smooth muscle cells, endothelial cells and neural cells [13].
Binding of IL-6 to soluble IL-6 receptor has been shown to be
proinflammatory, and has thus been implicated in the
pathogenesis of RA – making this pathway a target for
therapeutic interventions [13]. Recent studies have revealed
that selective blockade of this alternative IL-6 signalling
pathway using an engineered variant of soluble glycoprotein
Figure 1
Apolipoproteins protect from inflammation. Apolipoprotein (Apo) A-I
inhibits T-cell/monocyte interactions, thus blocking the production of
IL-1 and TNF and reducing inflammation. CRP, C-reactive protein;
SAA, serum amyloid A; HDL, high-density lipoprotein; sTL, stimulated
T lymphocyte; MΦ, macrophages. Figure kindly provided by 
Prof. Jean-Michel Dayer (Geneva, Switzerland).
Figure 2
Leptin produced by adipocytes can stimulate production of IL-1 by the
hypothalamus. Relationship between inflammation, adipocytes, IL-1
receptor antagonist (IL-1Ra), leptin, and obesity. Figure kindly provided
by Prof. Jean-Michel Dayer (Geneva, Switzerland).130 (sgp130Fc) led to substantial clinical improvement in a
preclinical arthritis model [14].
Although TNFα has been implicated in the pathogenesis of
RA, it also plays an important role in host defence, with
complete TNFα blockade associated with an increased risk
of mycobacterial infection [15]. Professor Sergei Nedospasov
(Berlin, Germany and Moscow, Russia) described in detail
the development of a novel humanized murine model for the
study of TNFα in collagen-induced arthritis [16]. In this
heterozygous model, both alleles are active – producing
human and murine TNFα, and thus allowing detailed compari-
son of human versus mouse regulation of TNFα expression. In
the homozygous model, approximately 40 to 50% of
humanized mice will develop arthritis (mediated by human
TNFα), which can be treated clinically using TNF blockers.
Using this, and several other murine models that they have
developed, Professor Nedospasov and his team aim to
determine the source of TNFα that protects against infection
and to develop TNFα inhibitors that target specific cell types
or compartments in the body where TNFα is overproduced.
Session 2 continued the theme of cytokines in arthritis and
began with an overview of the biological role of IL-1 and its
novel homologue IL-33 in inflammatory responses. The original
members of the IL-1 superfamily were IL-1α, IL-1β and IL-1Ra;
however, several additional molecules with structural homo-
logy have been added to this family in recent years, namely
IL-1F5, IL-1F6, IL-1F7, IL-1F8, IL-1F9, IL-1F10, IL-18 and
IL-33 (Figure 3). Professor Cem Gabay (Geneva, Switzerland)
discussed how the balance between IL-1and IL-1Ra
influences the development and severity of arthritis. Using
conditional knockout mice in which the expression of IL-1Ra
has been selectively targeted in myeloid cells, Professor
Gabay’s group showed that these mice had a more rapid
onset and severe form of collagen-induced arthritis with lower
levels of IL-1Ra in lymph nodes and increased Th1 and Th17
responses [17]. IL-33 – which binds to a member of the IL-1
receptor family, inducing similar intracellular signals to IL-1 –
is also expressed in human synovial fibroblasts with increased
expression in arthritic joints of murine models, suggesting a
potential role in the pathogenesis of arthritis [18].
Interferons are a family of naturally secreted proteins with
immunomodulatory functions. IFNβ has anti-inflammatory
properties and plays a role in bone homeostasis. IFNβ
treatment has been shown to reduce the severity of collagen-
induced arthritis in mice [19,20] and rhesus monkeys [21].
Conversely, IFNβ deficiency resulted in the development of
severe collagen-induced arthritis in mice as a result of
increased activation of stromal cells and osteoclasts [22].
After reviewing the lack of efficacy of subcutaneous injections
of IFNβ protein three times weekly for the treatment of RA
[23], Dr Margriet Vervoordeldonk (Amsterdam, The Nether-
lands) went on to discuss the potential of intra-articular IFNβ
gene therapy for the treatment of RA. In a set of proof-of-
principle studies using an adenoviral vector and recombinant
adeno-associated virus type 5 for local delivery of the rat
IFNβ gene [24,25], a beneficial effect has been shown on
arthritis development in two different rat models of arthritis.
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Figure 3
The IL-1 superfamily. The original members of the IL-1 superfamily were IL-1α, IL-1β and IL-1 receptor antagonist (IL-1Ra). IL-1F5, IL-1F6, IL-1F7,
IL-1F8, IL-1F9, IL-1F10, IL-18 and IL-33 have been added to this family in recent years owing to their structural homology. NF-HEV, nuclear factor
from high endothelial venules. Figure kindly provided by Dr John Sims (Amgen Inc., Thousand Oaks, CA, USA).Local delivery of adenoviral vector or recombinant adeno-
associated virus type 5 vectors expressing rat IFNβ after the
onset of disease reduced paw swelling impressively in both
injected and uninjected joints. Strikingly, IFNβ treatment
protected against bone and cartilage erosions. Together, the
results provide a rationale for IFNβ as a therapeutic target for
intra-articular gene therapy for arthritis.
Granulocyte–macrophage colony-stimulating factor (GM-
CSF) has been shown to be produced locally in the synovium
of individuals with RA, but not in those with osteoarthritis
[26,27]. Dr Christine Plater-Zyberk (Munich, Germany) des-
cribed the validation of an anti-GM-CSF monoclonal antibody
(22E9) for the treatment of RA, and noted how administration
of this antibody decreased arthritis severity in several experi-
mental models [28-30]. Dr Plater-Zyberk went on to discuss
the development of MT203, a human anti-GM-CSF antibody
with subnanomolar affinity and a very slow off-rate, which has
been derived from phage display-guided selection. MT203
has been shown to be stable in human serum and to inhibit
the production of IL-8 at subnanomolar concentrations.
Preclinical studies suggest that MT203 may be useful for the
treatment of RA and other indications, including psoriasis and
multiple sclerosis. The first clinical trial application for MT203
was submitted in Europe early in 2009 and the trial has now
started.
Cytokines and T-cell regulation
The first presentation in the next session of the meeting was
given by Professor Max Löhning (Berlin, Germany) and focused
on memory imprinting of T cells by cytokines. Immunological
memory, which can be defined as a more rapid response in
antigen-primed individuals, is a key characteristic of the
adaptive immune system. Increasing the availability of T cells
reactive to specific antigens is the aim of the majority of
vaccinations and immune cell therapies. Professor Löhning
described a series of experiments to identify how IFNγ and
IL-12, as opposed to IL-4 or IL-6 and transforming growth
factor beta, induce the differentiation of relatively short-lived
naïve T cells into long-lived memory T cells with distinct func-
tional properties (Figure 4) [31,32].
Techniques that may be employed to manipulate the cytokine
environment using tolerogenic dendritic cells were presented
by Professor John Isaacs (Newcastle, UK). Dendritic cells are
antigen-presenting cells that initiate and orchestrate immune
responses. By generating tolerogenic dendritic cells, it is
possible to downregulate immune responses. Tolerogenic
dendritic cells have been generated by culturing monocytes in
the presence of IL-4 and GM-CSF and then exposing them to
immunosuppressive agents such as dexamethasone [33].
Tolerogenic dendritic cells have been shown to be highly
stable and refractory to further stimulation by either lipopoly-
saccharide or peptidoglycan. They also maintain their tolero-
genic phenotype in a proinflammatory cytokine environment.
Professor Isaacs described preclinical studies where intra-
venous administration of tolerogenic dendritic cells has been
shown to decrease the severity of inflammatory arthritis and to
inhibit disease progression. Studies in humans are planned in
the near future, and it is hoped that this approach may provide
a route for immune reprogramming in autoimmunity.
An update on IL-17 and the growing IL-17 family of cytokines
was provided by Professor Pierre Miossec (Lyon, France).
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Figure 4
Role of cytokines in T-cell differentiation. Effector cytokine induction is part of Th-cell differentiation programmes – Th1 inducers? ROR, retinoic
acid-related orphan receptor; T-bet, T-box expressed in T-cells; TCR, T-cell receptor; TGF, transforming growth factor; Treg, regulatory T cell.
Figure kindly provided by Prof. Max Löhning (Berlin, Germany).Studies have shown production of functional IL-17 by RA
synovium explants and have shown that overexpression of
IL-17 in the knee joint of mice induces bone destruction and
cartilage damage [34]. A whole family of IL-17 molecules,
now known as IL-17A to IL-17F, has been identified together
with a range of IL-17 receptors. The highest degree of
homology (50%) is observed between IL-17A and IL-17F,
both of which are associated with the pathogenesis of RA
[35]. In contrast, IL-17E displays the lowest level of homology
with IL-17A (17%) and has not been shown to play any role in
RA [36-38]. IL-17 has been shown to induce the expression
of IL-1, IL-6, IL-8, GM-CSF and TNFα, all of which may
contribute to the pathogenesis of RA. In concluding,
Professor Miossec noted that the biology of IL-17A indicates
a role in the development of inflammation and joint destruc-
tion, and that the contribution of other IL-17 family members
to this process must be considered. Different novel thera-
peutic approaches targeted at these pathways are now under
investigation with interesting preliminary results.
The role of IL-17 in autoimmune disease was discussed
during a presentation given by Professor Thomas Kamradt
(Jena, Germany). The pathogenesis of autoimmune diseases
was previously thought to be largely driven by IL-12 acting via
Th1 cells. Knockout studies, however, have revealed an
increased susceptibility to autoimmunity when the p35 chain
of the IL-12 receptor is removed. These findings resulted in
the hypothesis that Th17 cells underlie the majority of auto-
immune diseases and are therefore a good target for the
development of novel therapies [39]. More recent research
has demonstrated that T cells isolated from inflammatory
lesions often co-express IL-17 together with IFNγ (the proto-
typical Th1 cytokine) and TNFα. A major current topic of
investigation into Th17 cells is the question of whether Th
cells form a stable memory for IL-17 expression [40].
Cytokines related to B-cell functions
The role of two cytokines that belong to the TNFα family –
B-cell activating factor (BAFF), which plays a role in the
development and survival of autoreactive B-cells, and a
proliferation-inducing ligand (APRIL), which promotes B-cell
activation and survival together with the humoral immune
response – were considered during a presentation by
Professor Thomas Dörner (Berlin, Germany). Both BAFF and
APRIL have been found to be elevated in autoimmune
diseases such as RA, systemic lupus erythematosus,
Sjögren’s syndrome, autoimmune thrombocytopenia and
autoimmune polyglandular syndrome type 1, and so have
become potential therapeutic targets. Professor Dörner out-
lined a number of studies using the monoclonal antibody
belimumab to inhibit BAFF [41-46]. Although the clinical
efficacy of this approach, particularly in RA, has not so far
been convincing, a recent press release (GSK/HGS)
reported positive results of the use of belimumab (anti-
BAFF/BLyS) in a 1-year trial of systemic lupus erythema-
tosus (BLISS-52). Finally, Professor Dörner speculated that
targeting the events that lead to BAFF production may be
more successful.
The role of B cells in autoimmune diseases was further
discussed during a presentation by Dr Simon Fillatreau
(Berlin, Germany). Murine models of multiple sclerosis have
been employed in an attempt to elucidate the interactions
that may occur between cytokines, B cells and T cells. Experi-
mental autoimmune encephalomyelitis, induced by immuniz-
ing mice with myelin proteins, is mediated by Th1 and Th17
CD4+ T cells and is clinically manifested by paralysis.
Experiments have shown that recovery from experimental
autoimmune encephalomyelitis requires the production of
IL-10 by B cells [47]. Myeloid differentiation primary response
gene 88 is a universal adapter protein that signals via Toll-like
receptors to activate the transcription factor NF-κB and
trigger the regulatory function of B cells, and hence control
the inflammatory T-cell response. In addition, B-cell activation
via the B-cell receptor and CD40 has also been implicated in
recovery from experimental autoimmune encephalomyelitis. A
two-step process whereby B cells limit inflammation and aid
recovery from experimental autoimmune encephalomyelitis
thus operates within this murine model. Firstly, myeloid
differentiation primary response gene 88 signalling in B cells
induces potent anti-inflammatory cascades capable of
suppressing chronic immune responses. Secondly, the B-cell
receptor and CD40 then act to amplify these B-cell-mediated
cascades. These findings may have implications for the study
of multiple sclerosis in humans.
In addition to its involvement in metabolism and energy
balance, adipose tissue has been suggested to play a role in
the immune system via the secretion of cytokines known as
adipokines. Adipokines such as adiponectin, visfatin and
resistin have all been implicated in the pathogenesis of RA.
Dr Elena Neumann (Giessen, Germany) described a number
of studies that suggest adipokines may play a role in RA by
modulating inflammatory and/or destructive mechanisms
[48,49]. For example, both adiponectin and visfatin have
been shown to have several destructive effects in RA,
inducing proinflammatory factors, chemokines and matrix-
degrading enzymes [50-53]. Studies in murine models,
however, suggest that adiponectin may mitigate the severity
of arthritis [54,55] – suggesting either that different isoforms
of adiponectin exist or that different signalling cascades may
be activated in different tissues. The role of resistin in
inflammation, and thus RA, is less clear and requires further
investigation.
Genetic aspects of cytokine regulation
A comprehensive review of the genomic aspects of auto-
immunity was provided by Professor Gerd Burmester (Berlin,
Germany). Professor Burmester discussed the various
techniques available for gene expression profiling, together
with the importance of optimal sample selection. Gene
expression profiling of synovial tissue taken from individuals
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dominance of cell infiltration-related changes. Interestingly,
these techniques have also allowed analysis of gene
expression in patients who did not respond to therapy, with
nonresponding patients treated with anti-TNF showing similar
genetic profiles to untreated patients.
Further insight into the genetics underlying cytokine regula-
tion was provided in a presentation by Dr Leonid Padyukov
(Stockholm, Sweden). Genetic polymorphisms can have
functional consequences, mainly due to variation in regulatory
sequences. Studying genetic predisposition is therefore
important in the most homogeneous subgroup of the disease
available. For example, autoantibodies to citrullinated proteins
have been observed in 60 to 70% of patients with RA, and
their early appearance suggests a possible role in the
pathogenesis of this disease [56]. It has been suggested that
the majority of genetic polymorphisms associated with RA are
restricted to those individuals with autoantibody-positive
disease and are found in only a few individuals with
autoantibody negative RA [57].
Key cytokines related to autoimmunity
The final session of the meeting focused on the key cytokines
that have been shown to play a role in autoimmunity: type I
interferon, IFNα, IL-12, IL-23 and IL-21.
Professor Peggy Crow (New York City, USA) discussed how
microarray analyses have enabled the identification of genetic
signatures in the peripheral blood of individuals with auto-
immune diseases. In addition, increased IFNα pathway
activation has been associated with increased autoimmunity
together with increased inflammation and tissue damage.
Continuing on the same theme, Professor Lars Rönnblom
(Uppsala, Sweden) concurred that administration of IFNα can
cause autoimmune disease and that many patients with auto-
immune conditions have an ongoing production of IFNα.
Moreover, anti-IFNα antibodies applied in preclinical and early
clinical trials have been shown to attenuate autoimmunity.
Professor Joachim Sieper (Berlin, Germany) provided an
overview of clinical data that clearly demonstrated the
benefits of IL-12 and IL-23 blockade in individuals with
psoriasis [58,59]. This approach has proved less beneficial in
individuals with either Crohn’s disease or psoriatic arthritis.
Moreover, further investigations are required in order to
establish whether joint IL-12 and IL-23 blockade is required,
or whether blockade of IL-23 alone would be sufficient for the
treatment of autoimmunity.
A comprehensive review of the properties of IL-21 and the
IL-21 receptor was provided by Professor Peter Lipsky
(Bethesda, MD, USA). Professor Lipsky outlined the role
played by IL-21 in B-cell differentiation and T cell–B cell
interactions, and commented that IL-21 is a new target for the
downregulation of B-cell responsiveness (Figure 5). After
noting that IL-21 is elevated in individuals with systemic lupus
[60], Professor Lipsky speculated on the possible benefit to
these individuals of effective IL-21 blockade.
Conclusions
In bringing this meeting to a close, Professor Burmester
thanked all of the speakers for their thought-provoking
presentations at a most enjoyable and interesting meeting.
He commented on how pleased Professor Kitasato would
have been with the advances that have been made within the
field of cytokine research. Significant advances have been
made in identifying the proinflammatory pathways that
underlie the pathogenesis of RA and other autoimmune
diseases. By building upon the research that was presented
at this first Kitasato Symposium, it may be possible to
develop new, more targeted therapies with the potential to
significantly improve the prognosis for those individuals
affected by autoimmunity.
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Figure 5
Properties of IL-21 and the IL-21 receptor. IL-21 plays a role in B-cell
differentiation and T cell–B cell interactions, and is elevated in
individuals with systemic lupus erythematosus.References
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